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In tissue culture models, low pH is a promising target for
improved chemotherapy (Wike-Hooley et al, 1984; Volk et al,
1993). An acidic environment enhances the uptake of weak acids
(Mikkelsen et al, 1985; Jähde et al, 1989) and topoisomerase I
inhibitors (Gabr et al, 1997), it also increases the activation of
bioreductive agents (Gibson et al, 1992; Philips et al, 1992;
Begleiter and Leith, 1993) and potentiates the interaction of alkyl-
ating agents and platinum-containing drugs with DNA (Jähde et al,
1989; Atema et al, 1993). Because conditions of low pH in cell
culture include a simultaneous reduction in the intracellular pH
(Atema et al, 1993), studies in vitro cannot discriminate between
the contribution of reduced extra- or intracellular pH in the
observed potentiations.
Tumour-selective acidification can be achieved in animal
and human tumours by stimulation of their intrinsically high glyco-
lytic flux by glucose infusion alone (Jähde and Rajewsky, 1982;
Thislethwaite et al, 1987) or with coadministration of the mito-
chondrial inhibitor m-iodobenzylguanidine (MIBG) (Kuin et al,
1994), and by administration of vasoactive drugs like hydralazine
(Newell et al, 1992). 31P Magnetic resonance spectroscopy (MRS)
studies have revealed that only the extracellular pH (pHe) is
reduced by these interventions (Hwang et al, 1991; Kuin et al,
1994), which restricts their application in vivo to weakly acidic
drugs, acid labile prodrugs (Tietze et al, 1989) and camptothecins
(Gabr et al, 1997).
Some studies, therefore, have concentrated on reduction of the
intracellular pH (pHi) of tumours by inhibition of membrane-based
exchangers involved in the regulation of pHi. The two major
exchangers are the Na+/H+ antiport, which can be inhibited by
amiloride and its analogues, and the Na+-dependent HCO3
–/Cl–
exchanger, inhibited by stilbene derivatives such as 4,4¢-diisothio-
cyanostilbene-2,2¢-disulphonic acid (DIDS). Furthermore, the
ionophore nigericin is able to reduce the pHi by allowing exchange
of intracellular K+ for extracellular H+ (Rotin et al, 1987; Newell
and Tannock, 1989; Yamagata and Tannock, 1996). Wood et al
(1995) have shown that equilibration of the pHi with pre-existing
low pHe of a radiation-induced fibrosarcoma (RIF-1) tumour by
nigericin can potentiate melphalan-related tumour response,
whereas a combination of DIDS with amiloride increased the
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Summary Tumour-selective acidification is of potential interest for enhanced therapeutic gain of pH sensitive drugs. In this study, we
investigated the feasibility of a tumour-selective reduction of the extracellular and intracellular pH and their effect on the tumour response of
selected anti-cancer drugs. In an in vitro L1210 leukaemic cell model, we confirmed enhanced cytotoxicity of chlorambucil at low extracellular
pH conditions. In contrast, the alkylating drugs melphalan and cisplatin, and bioreductive agents mitomycin C and its derivative EO9, required
low intracellular pH conditions for enhanced activation. Furthermore, a strong and pH-independent synergism was observed between the pH-
equilibrating drug nigericin and melphalan, of which the mechanism is unclear. In radiation-induced fibrosarcoma (RIF-1) tumour-bearing
mice, the extracellular pH was reduced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) or its analogue benzylguanidine (BG)
plus glucose. To simultaneously reduce the intracellular pH, MIBG plus glucose were combined with the ionophore nigericin or the Na+/H+
exchanger inhibitor amiloride and the Na+-dependent HCO3
–/Cl– exchanger inhibitor 4,4¢-diisothiocyanostilbene-2,2¢-disulphonic acid (DIDS).
Biochemical studies confirmed an effective reduction of the extracellular pH to approximately 6.2, and anti-tumour responses to the
interventions indicated a simultaneous reduction of the intracellular pH below 6.6 for at least 3 h. Combined reduction of extra- and
intracellular tumour pH with melphalan increased the tumour regrowth time to 200% of the pretreatment volume from 5.7 ± 0.6 days for
melphalan alone to 8.1 ± 0.7 days with pH manipulation (P < 0.05). Mitomycin C related tumour growth delay was enhanced by the combined
interventions from 3.8 ± 0.5 to 5.2 ± 0.5 days (P < 0.05), but only in tumours of relatively large sizes. The interventions were non-toxic alone
or in combination with the anti-cancer drugs and did not affect melphalan biodistribution. In conclusion, we have developed non-toxic
interventions for sustained and selective reduction of extra- and intracellular tumour pH which potentiated the tumour responses to selected
anti-cancer drugs.
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Moreover, because a protracted lowering of the intracellular pH can
be cytotoxic by itself (Rotin et al, 1987), Yamagata and Tannock
(1996) were able to demonstrate that prolonged administration of
nigericin (6 mg kg–1) stopped net tumour growth during the infu-
sion time and achieved tumour reduction by nigericin combined
with DIDS and the amiloride analogue 5-(N-ethyl-N-isopropyl)
amiloride (EIPA), after lowering tumour pHe from 6.9 to approxi-
mately 6.8 by the vasoactive drug hydralazine.
Potentiation of anti-cancer drug activity and the cytotoxicity of
low pHi itself are dependent on both the duration and the degree of
tumour acidification (Rotin et al, 1987; Yamagata and Tannock,
1996). In an attempt to optimize pHi reduction, MIBG/glucose
treatment, which selectively reduces the extracellular pH down
to 6.2 for several hours (Kuin et al, 1994), was combined with
nigericin or amiloride and DIDS. To investigate the relative contri-
butions of reduced pHe and pHi on the cytotoxicity of several anti-
cancer drugs and the possible interference of MIBG with drug
action, unrelated to the pH-lowering capacity, we used for prac-
tical reasons a L1210 leukaemic cell model. Subsequently, we
investigated in RIF-1-bearing mice the optimal conditions of a
non-toxic protocol of MIBG/glucose treatment in combination
with nigericin or amiloride and DIDS. The analogue benzylguani-
dine (BG), with comparable antimitochondrial effects, was used as
an alternative for MIBG to avoid nephrotoxicity associated with
high dose MIBG (Kuin et al, 1998). Finally, we investigated the
effect of low pHe and pHi on the in vivo tumour response to the
anti-cancer drugs chlorambucil, mitomycin C and melphalan.
MATERIALS AND METHODS
Drugs
MIBG was purchased from EMKA Chemie (Markgröningen,
Germany). BG was synthesized as described before (Van den Berg
et al, 1997). D(+)glucose monohydrate was obtained from Merck
(Darmstadt, Germany). 2-Deoxy-D-[1-3H]glucose (specific activity
17.4 Ci mmol–1) and [51Cr]EDTA (specific activity 1–2 mCi mg–1)
were purchased from Amersham International (Buckinghamshire,
UK). EO9 (3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-
4,7-dione)prop-b-en-a-ol) was kindly provided by Dr JH Beijnen
(Slotervaart Hospital, The Netherlands Cancer Institute,
Amsterdam, The Netherlands), cisplatin was obtained from Bristol-
Myers Squibb (Weesp, The Netherlands) and all other drugs were
from Sigma (St. Louis, MO, USA).
For in vitro experiments, mitomycin C and doxorubicin were
dissolved in sodium chloride 0.9% to 1 mg ml–1. Chlorambucil was
dissolved in DMSO (4 mg ml–1) and melphalan, EO9 and nigericin
in ethanol (99% v/v) to 0.5, 0.5 and 1 mg ml–1 respectively.
In animal experiments, a standard pharmaceutical preparation
of melphalan was used (Alkeran; Wellcome Foundation, UK)
and injected within 30 min after dissolving. Chlorambucil was
dissolved directly before use in acidified ethanol (4.8 ml concen-
trated hydrochloric acid in 95% v/v ethanol) and diluted 1:9 with
propylene glycol/dipotassium hydrogen phosphate buffer (20 g
dipotassium phosphate plus 450 ml propylene glycol in a final
volume of 1 l), final pH 7.4 (Lee et al, 1986). MIBG and BG were
dissolved during 16 h at 37°C in phosphate-buffered saline (PBS).
Before use, glucose was added to a concentration of 0.15
or 0.30 g ml–1. DIDS and amiloride were dissolved in PBS and
demineralized water respectively.
Cells and experimental conditions
L1210 murine leukaemia cells were routinely cultured in RPMI-
1640 medium (Gibco Europe, The Netherlands), supplemented
with 10% fetal calf serum (Gibco Europe), 100 U ml–1 penicillin,
100 mg ml–1 streptomycin and 60 mM b-mercaptoethanol, at 37°C
in a humidified atmosphere with 5.6% carbon dioxide. The popu-
lation doubling time was 12 h.
During MIBG exposure (10 mg ml–1) for 4 h, cells were incu-
bated at a density of 5 ´ 106 cells ml–1 in RPMI-1640 medium
without sodium bicarbonate (Gibco Europe). The intracellular pH
was measured by using the fluorescent dye 2¢,7¢-bis(carboxyethyl)-
5,6-carboxyfluorescein-triacetoxymethylester (BCECF-AM) as
described previously (Atema et al, 1993). The extracellular pH was
recorded simultaneously with a silver/silver chloride/gel-filled/
sealed Broadley James electrode connected to a Becton Model 32
pH-meter. Glucose and lactate levels in the medium were estimated
before and after the incubation with MIBG by routine assays
(Boehringer Mannheim, Germany). ATP levels were measured at
different incubation periods: samples of ± 5 ´ 106 cells were
extracted with cold perchloric acid (0.5 M). The extracts were
neutralized with 2 M potassium hydroxide in 0.3 M 4-morpholino-
propane sulphonic acid and stored at –70°C. Samples were diluted
in 0.1 M Tris/2 mM EDTA (pH 7.75) and ATP was measured
fluorimetrically using luciferin-containing Monitoring Reagent
(BioOrbit, Finland). Intracellular ADP levels were converted to
ATP by adding phosphoenolpyruvate (3.2 mM) and pyruvate kinase
(0.16 mg ml–1). The increase in ATP content was used as a measure
for the ADP concentration. ATP and ADP levels were correlated
to the protein content determined according to the protocol of
Bradford (1976).
Cell survival experiments
For single cell survival experiments, anti-cancer drugs were added
at different concentrations to the cell suspension (5 ´ 106 cells
ml–1) during the last 2 h of the 4-h MIBG incubation period.
To test for the contribution of reduced extra- and intracellular
pH, cells (106 cells ml–1) were incubated during 4 h with anti-cancer
drugs at different pHe and pHi conditions. To this end, sodium
bicarbonate-free RPMI incubation medium was acidified with
lactic acid to pH 6.5, and nigericin (10 mM) was added to equilibrate
the pHi with the pHe. Incubations at pHe 6.5 without nigericin and
at pHe 7.4 with and without nigericin served as controls. The corre-
sponding pHi values were confirmed in parallel cultures.
After exposure, the cell suspensions were diluted with buffered
RPMI medium and suspended in a semisolid plating medium
consisting of RPMI-1640 supplemented with 20% conditioned
medium and 0.6% carboxymethylcellulose (Fluka, Buchs,
Switzerland). Cell suspensions of 10 ml, containing 300 or 3000
cells were divided over three wells of a six-well cluster plate
(Costar, Cambridge, MA, USA). Macroscopic colonies were
counted after 8–9 days and survival was calculated as percentage
of controls without anti-cancer drugs. Dose-reduction factors at
50% survival (DRF50) were calculated by dividing the IC50 at
physiological pH by that at low pH.
Animals and tumour acidification
All animal experiments were carried out in accordance with proto-
cols approved by the experimental animal welfare committee of the
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animal experimentation. According to inhouse rules, mice were
observed at least twice daily for treatments with unknown toxicity
and sacrificed at signs of severe discomfort and weight loss of 15%.
RIF-1 cells from liquid nitrogen stocks were propagated in
tissue culture and transplanted at restricted passage numbers
according to a previously described protocol (Twentyman et al,
1980). Cells (105 in 0.1 ml) were s.c. injected on the back of
syngeneic male C3H/Km mice weighing 28–35 g at an age of
8–10 weeks. Two weeks after inoculation, tumour diameters
reached 3–5 mm and treatment was started.
For tumour-specific acidification, mice were treated by MIBG
(30 mg kg–1) or BG (37 or 43 mg kg–1), in combination with
different doses of glucose (1.5 or 3.0 g kg–1). Doses were chosen
based on absence of reduced renal clearance and proven mitochon-
drial inhibition in vivo (Kuin et al, 1998). To assay for the effect on
tumour metabolism, glucose and lactate levels and deoxyglucose
uptake were measured as described previously (Kuin et al, 1994).
Briefly, for glucose and lactate measurements, tumours were
excised 3 h after treatment, frozen, ground to powder and
suspended in demineralized water. Glucose and lactate levels were
estimated by routine assays (Boehringer Mannheim) and related to
the protein content. 2-Deoxy-D-[1-3H]glucose (10 mCi 100 ml–1)
was administered i.v. 2 h after treatment. After 1 h, mice were
sacrificed and tumour samples of about 50 mg were extracted in
2 ml perchloric acid (0.5 M) during 48 h. Radioactivity of the
extracts was assessed by liquid scintillation counting and
expressed in percentage of injected dose g–1 tumour.
Tumour treatment protocols
For intracellular acidification, MIBG/glucose and BG/glucose
treatments were combined with amiloride and DIDS in doses up to
the maximum tolerated dose of 10 and 25 mg kg–1 respectively (IF
Tannock, personal communication). The drugs were injected at
low pHe conditions; 2.5 and respectively 3 h after MIBG/glucose
or BG/glucose treatment of which the 30 min interval served to
prevent intraperitoneal coprecipitation of the drugs. Melphalan
(8 mg kg–1) was injected at 3.5 h and mitomycin C, administered
in two doses of 2.5 mg kg–1, at 3.5 and 6.5 h after start of the treat-
ment. Chlorambucil (10 mg kg–1) was injected 3 h after MIBG/
glucose treatment without amiloride and DIDS.
Melphalan was injected i.v. and all other drugs i.p. in a volume
of 0.01 ml g–1 body weight. Control animals received corre-
sponding volumes of PBS. Tumour growth, measured by callipers
in three orthogonal diameters, was documented daily, as were
body weight and general wellbeing. Tumour response was
expressed as the regrowth time to 200% of the pretreatment
volume.
Renal function and melphalan distribution
Renal function was measured by [51Cr]EDTA clearance as
described previously (Kuin et al, 1998). In short, 4.5 h after
MIBG/glucose treatment, mice were injected i.p. with 10 mCi
[51Cr]EDTA in 100 ml. Thirty minutes after the injection, blood
samples were taken from the retro-orbital sinus and mice were
sacrificed. Plasma [51Cr]EDTA levels were determined by gamma
counting and expressed as percentage of injected dose per ml
plasma. Increases in residual plasma [51Cr]EDTA levels reflect a
reduced renal clearance.
The effect of the treatment with MIBG/glucose plus amiloride/
DIDS on melphalan pharmacokinetics was investigated by taking
blood samples and excising the tumour 15, 60 and 120 min after
melphalan injection. Plasma and tumour tissue were frozen until
analysis of melphalan concentrations by high-performance liquid
chromatography (HPLC) assay (Klaase et al, 1994). Mice were
sacrificed immediately after blood sampling.
Statistical analysis
Significance of differences in mean values was determined by
Student’s t-test. A P-value <0.05 was judged to be of statistical
significance.
RESULTS
Antiproliferative and metabolic effects of MIBG on
L1210 cells
MIBG at 10 mg ml–1 inhibited the mitochondrial respiration of
L1210 cells, comparable as described previously (Loesberg et al,
1990), resulting in enhanced glucose consumption (control, 0.32 ±
0.04 mmol 106 cells–1 4h –1; MIBG, 0.54 ± 0.06 mmol 106 cells–1
4h –1) and lactate production (control, 0.56 ± 0.08 mmol 106 cells–1
4h –1; MIBG, 0.94 ± 0.04 mmol 106 cells–1 4h –1). The pH of the
sodium bicarbonate-free incubation medium decreased down to
pH 6.2. Addition of recorded amounts of lactate to fresh medium
revealed that lactate production alone was responsible for the
decrease in pH. The intracellular pH also decreased but a pH
gradient of 0.6 pH units was maintained (Figure 1), corresponding
to previous studies with acidification by addition of lactic acid
(Atema et al, 1993). The pHe of control cells at this high cell
density did not decrease below pH 6.8.
The ATP levels remained stable during the incubation period
and were equal for untreated (26 ± 3 mmol ATP g–1 protein) and
MIBG-exposed cells (25 ± 4 mmol ATP g–1 protein). ADP levels
were below detection levels at both conditions, indicating an
unchanged and high energy state after MIBG treatment. The
plating efficiency of the L1210 cells (>80%) was not affected by
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Figure 1 Extracellular (open symbols) and intracellular pH (closed symbols)
of L1210 cells at high cell density (5´106 cells ml–1) exposed to MIBG
(10 mg ml–1) during 4 h, measured by pH electrode and the fluorescent dye
BCECF-AM respectively. Means ± s.d. of three individual experiments. Error
bars if not shown are within the size of the symbolsMIBG-induced decrease in pH under these experimental
conditions.
The adherent RIF-1 cells could not be brought to high cell
densities or used in convenient FACS-assisted pHi measurements
and were therefore not suitable for these in vitro studies.
Cytotoxicity of anti-cancer drugs to L1210 cells at
physiological and low pH
After 2 h preincubation with MIBG, several anti-cancer drugs in
increasing concentrations were added for another 2 h. The low pH
induced by MIBG protentiated the cytotoxicity of the anti-cancer
drugs melphalan, cisplatin, mitomycin C, EO9, and chlorambucil,
whereas doxorubicin was less cytotoxic at low pH compared with
physiological pH conditions. The level of potentiation of the drugs
is expressed in Table 1 as the dose-reduction factor at 50%
survival (DRF50). Moreover, if MIBG was added at physiological
pH to buffered RPMI medium, the pH was not affected and no
enhancement was observed with melphalan, EO9 or chlorambucil,
excluding a synergistic effect of MIBG with the cytostatic drugs
per se.
To specifically investigate the role of low pHi in the observed
potentiations, we compared survival after a 4-h incubation period
at pHe 7.4 and 6.5, with and without nigericin (1 mM). Addition of
lactic acid to reach a pHe of 6.5 was accompanied by a shift of the
pHi from 7.3 to 7.0, which further decreased to pH 6.5 within
5 min after addition of nigericin. The latter condition was not
toxic to the cells for a 4-h incubation (plating efficiency >70%).
However, at pHe values below 6.5, addition of nigericin caused a
steep decline in survival (e.g. <0.1% at pHe 6.0) in both L1210
and RIF-1 cells, exactly as reported by other groups (Rotin et al,
1987; Newell and Tannock, 1989). Therefore, to investigate
effects of low pHi on the cytotoxicity of anti-cancer drugs,
excluding confusing intrinsic toxicity, no pHi conditions below
pHi 6.5 were used.
In medium of pH 6.5, melphalan was much more cytotoxic in the
presence of nigericin (pHi 6.5) than without nigericin (pHi 7.0) with
a DRF50 of 11.5 (Figure 2), suggesting that a decrease in pHi of
0.5 units (Figure 1) is mainly responsible for the potentiation
observed. However, in control experiments at physiological intra-
and extracellular pH, nigericin also potentiated the melphalan-related
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Table 1 Dose-reduction factors (DRF) of a 2-h exposure time of several
anti-cancer drugs to L1210 cells calculated by the IC50 at physiological pH
conditions over the IC50 after incubation at low pH (down to pH 6.2) due to
MIBG exposure. Results represent mean ± s.d. of 3–5 experiments. The
relevant pH condition is deduced from results of experiments demonstrated
in Figures 2, 3 and 4
DRF 50% pH Condition
Cisplatin 2.0 ± 0.4 pHi
Mitomycin C 1.3 ± 0.3 pHi
EO9 6.2 ± 1.5 pHi
Melphalan 2.8 ± 0.6 pHi
Chlorambucil 2.2 ± 0.4 pHe
Doxorubucin 0.64 ± 0.07 pHe
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Figure 3 Survival of L1210 cells (106 cells ml–1) after a 4-h exposure to EO9
at low pHe conditions acidified by lactic acid (triangles) or at physiological
pHe (circles), with (closed symbols) or without (open symbols) nigericin to
equilibrate pHe with pHi. Means ± s.d. of three individual experiments
Figure 4 Survival of L1210 cells (106 cells ml–1) after a 4-h exposure to
chlorambucil at low pHe conditions acidified by lactic acid (triangles) or at
physiological pHe (circles), with (closed symbols) or without (open symbols)
nigericin to equilibrate pHe with pHi. Means ± s.d. of three individual
experiments
Figure 2 Survival of L1210 cells (106 cells ml–1) after a 4-h exposure to
melphalan at low pHe conditions acidified by lactic acid (triangles) or at
physiological pHe (circles), with (closed symbols) or without (open symbols)
nigericin to equilibrate pHe with pHi. Means ± s.d. of three individual
experiments
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0.0 0.2 0.4 0.6 1.0 0.8cell kill with a DRF50 of 3.8. This unexpected, pH-independent syner-
gism was specific for the combination of melphalan and nigericin
and not found for cisplatin, mitomycin C, E09, chlorambucil or
doxorubicin. Moreover, amiloride and DIDS in non-toxic concentra-
tions of 0.2 mM and 1 mM, respectively, did not enhance melphalan
toxicity at pH 7.4. Attempts to directly test the pHi effect on
melphalan cytotoxicity by replacing nigericin with amiloride and
DIDS were inconclusive because the time to equilibrate pHi with
pHe by these drugs took up to 3 h, and prolonged exposure to
amiloride and DIDS at pH 6.5 was toxic on its own.
As for melphalan, cytotoxicity of E09 was not enhanced at
pHe 6.5 (Figure 3), but strongly potentiated after simultaneous
reduction of the pHi to 6.5. In comparable experiments with mito-
mycin C and cisplatin, the potentiations were also mainly due to a
reduced pHi, as summarized in Table 1. In contrast, the cytotoxi-
city of chlorambucil was strongly potentiated at pHe 6.5 (Figure
4), but not further enhanced by simultaneous pHi reduction by
nigericin. Similar experiments with doxorubicin confirmed the
reported inhibition of its cytotoxicity at low pHe conditions
(Alabaster et al, 1989). From this screen, chlorambucil would
appear the most interesting drug to combine in animal studies
with MIBG/glucose treatment alone, whereas potentiation of
melphalan, mitomycin C, EO9 and cisplatin requires the inclusion
of pH-equilibrating drugs in the protocols.
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Table 2 Tumour acidification after MIBG or BG treatment combined with glucose, related to tumour lactate levels and [3H]deoxyglucose uptake
Tumour lactate levels [3H]Deoxyglucose uptake
(mmol g–1 protein) (% uptake g–1 tumour)
PBS 0.45 ± 0.09a 2.7 ± 1.8
MIBG 40 mg kg–1 + glucose 1.5 g kg–1b 0.60 ± 0.22c 4.1 ± 0.7c
MIBG 30 mg kg–1 + glucose 1.5 g kg–1 0.66 ± 0.13c 4.5 ± 2.4c
BG 43 mg kg–1 + glucose 1.5 g kg–1 0.42 ± 0.05 5.4 ± 1.1c
BG 43 mg kg–1 + glucose 3.0 g kg–1 0.64 ± 0.08c n.d.d
aMean ± s.d. of 6–8 animals; bKuin et al (1994); cDifferent from control, P < 0.05; dnot determined.
Table 3 Renal function measured by [51Cr]EDTA clearance. [51Cr]EDTA was injected 4.5 h after MIBG or BG treatment and 30 min
later residual plasma levels were measured
Treatment [51Cr]EDTA clearance
t = 0 t = 2.5 h t = 3 h
(% [51Cr]EDTA ml–1 plasma)
PBS 1.9 ± 0.5a
MIBG 40/glucose 1.5b 4.0 ± 1.6c
MIBG 30/glucose 1.5 2.0 ± 0.2
MIBG 30/glucose 1.5 Amiloride 5 DIDS 12.5 2.2 ± 2.2
MIBG 30/glucose 1.5 Amiloride 10 DIDS 25 4.4 ± 0.7c
BG 43/glucose 1.5 Amiloride 10 DIDS 25 2.2 ± 0.5
BG 37/glucose 3.0 Amiloride 10 DIDS 25 3.3 ± 0.5c
BG 37/glucose 3.0 3.2 ± 0.4c
Glucose 3.0 3.4 ± 0.3c
aMean ± s.d. of six animals; bKuin et al (1998); cDifferent from control, P < 0.05.
Table 4 Tumour response to the interventions alone and in combination with melphalan expressed
as the tumour regrowth time to 200% of day 0
Regrowth time (days)
mean ± s.d. (n = 6–8)
Control 1.5 ± 0.7
MIBG/glucose + amiloride DIDSa 2.2 ± 0.4c
BG/glucose + amiloride DIDSb 2.5 ± 0.3c
Melphalan 5.7 ± 0.6
MIBG/glucose + melphalan 6.8 ± 0.9c
BG/glucose + melphalan 6.9 ± 1.7
Amiloride/DIDS + melphalan 6.7 ± 0.7d
MIBG/glucose + amiloride/DIDS + melphalan 7.4 ± 0.8d
BG/glucose + amiloride/DIDS + melphalan 8.1 ± 0.7d
a5 mg kg–1 amiloride/12.5 mg kg–1 DIDS; b10 mg kg–1 amiloride/25 mg kg–1 DIDS; cDifferent from
control, P <0.05; dDifferent from melphalan alone, P < 0.05.Tumour acidification
To simultaneously reduce extra- and intracellular tumour pH, we
combined the intervention MIBG/glucose with pH-equilibrating
drugs nigericin or amiloride and DIDS. In previous studies, we
have demonstrated that 40 mg kg–1 MIBG plus 1.5 g kg–1 glucose
reduces tumour pH for several hours down to pH 6.2 (Kuin et al,
1994) without affecting tumour growth (Gabr et al, 1997). Inclusion
of 10 mg kg–1 amiloride and 25 mg kg–1 DIDS to this
MIBG/glucose protocol induced a significant anti-tumour response,
i.e. a reduction of tumour volume after 2 days to 59% ± 27% of the
pretreatment value with a corresponding increase in tumour
regrowth time from 1.5 to approximately 4.3 days. Similar results
were obtained with nigericin (1.5 mg kg–1) if administered between
1 and 6 h after MIBG/glucose treatment (A Gabr, personal commu-
nication). These experiments indicate that nigericin and amiloride
plus DIDS were able to reduce the intracellular pH below a critical
level for cell kill at an interstitial pH of 6.2. After MIBG at
40 mg kg–1 in combination with amiloride and DIDS, body weights
progressively decreased and animals were sacrificed when weight
loss exceeded 15%, mainly after resumption of tumour growth. The
combination of MIBG with nigericin did not significantly affect
body weights but caused acute lethality in one out of five mice.
Moreover, MIBG itself induces, at 40 mg kg–1, reversible reduction
in renal function (Kuin et al, 1998). A series of experiments was,
therefore, performed to establish conditions of tumour acidification
with minimal toxicity. In addition to lower doses of MIBG, we also
tested the MIBG analogue BG, which mimics the antimitochondrial
effects of MIBG but is less nephrotoxic (Van den Berg et al, 1997;
Kuin et al, 1998). Tumour pH response was evaluated biochemi-
cally by increases in tumour lactate levels and [3H]deoxyglucose
uptake in comparison to the previously described effects of
MIBG/glucose treatment (Table 2). BG at 43 mg kg–1 was only
effective in increasing tumour lactate levels when combined with
3.0 g kg–1 glucose. This higher dose of glucose did neither change
tumour lactate levels when given alone nor further enhance tumour
lactate levels when combined with MIBG (data not shown).
Addition of i.v. injected melphalan to BG/glucose resulted in acute
effects, sometimes even lethal. Therefore, the BG dose was
decreased to 37 mg kg–1, i.e. twice the molar dose of 30 mg kg–1
MIBG, which did not demonstrate these acute effects.
Table 3 summarizes the effects of the various treatments
including amiloride and DIDS on renal function measured by
[51Cr]EDTA clearance. High doses of glucose (3 g kg–1) affect
the [51Cr]EDTA kinetics independent of renal toxicity as
described previously (Kuin et al, 1998). The ionophore nigericin
(1.5 mg kg–1) slightly reduced renal function when given alone
(from 1.8% ± 0.3% to 2.7% ± 0.8% [51Cr]EDTA ml–1 plasma;
P = 0.03) or in combination with 37 mg kg–1 BG plus 3.0 g kg–1
glucose (3.7% ± 2.2% [51Cr]EDTA ml–1 plasma; P = 0.09), but
strongly affected renal function when combined with 30 mg kg–1
MIBG plus 1.5 g kg–1 glucose (6.9% ± 1.6% [51Cr]EDTA ml–1
plasma; P < 0.001).
The finally chosen non-toxic interventions were 30 mg kg–1
MIBG plus 1.5 g kg–1 glucose followed by 5 mg kg–1 amiloride (t =
2.5 h) and 12.5 mg kg–1 DIDS (t = 3 h), and 37 mg kg–1 BG plus
3.0 g kg–1 glucose followed by 10 mg kg–1 amiloride and
25 mg kg–1 DIDS at similar intervals. These will be referred to in
further experiments as MIBG/glucose plus amiloride/DIDS and
BG/glucose plus amiloride/DIDS respectively.
Tumour response to anti-cancer drugs after reduction
of extra- and intracellular pH
The two interventions described above each induced a slight but
significant delay in tumour regrowth time (Table 4), but had no
effect without amiloride and DIDS (data not shown).
Because chlorambucil was in vitro specifically potentiated
at a low extracellular pH (Figure 4), this drug was tested
after MIBG/glucose treatment without amiloride and DIDS.
Chlorambucil (10 mg kg–1) caused an increase in tumour growth
delay from 1.5 ± 0.8 to 5.3 ± 0.6 days (P < 0.001), but in contrast
to the in vitro results the tumour response was not enhanced
by a preceding MIBG/glucose treatment (tumour regrowth time
5.8 ± 0.9 days; P = 0.15).
Under standard conditions, the response to mitomycin C
(tumour regrowth time 3.8 ± 1.0 days) was enhanced neither by
MIBG/glucose or BG/glucose alone nor in combination with
amiloride and DIDS. However, a significantly enhanced response
by MIBG/glucose plus amiloride/DIDS was observed in a pilot
experiment with large tumours of >5 mm diameter, increasing the
tumour regrowth time from 3.8 ± 0.5 for mitomycin C alone to
5.2 ± 0.5 days for the combined treatment (n = 6; P < 0.001).
The mitomycin C derivative EO9 demonstrated severe toxicity
at doses above 5 mg kg–1 that included peritoneal oedema, necrosis
of the intestines and, in some cases, acute peritonitis, liver toxicity
and hyperaemic bone marrow. Because the maximum tolerated
dose of 5 mg kg–1 did not result in a tumour response, studies with
EO9 were discontinued.
798 A Kuin et al
British Journal of Cancer (1999) 79(5/6), 793–801 © Cancer Research Campaign 1999
2000
1000
100
10
R
e
l
a
t
i
v
e
 
t
u
m
o
u
r
 
v
o
l
u
m
e
 
(
%
 
o
f
 
d
a
y
 
0
)
02468 1 0
Time (days)
Figure 5 Relative tumour growth of RIF-1 tumour in C3H/Km mice after
treatment with PBS (open circle), melphalan (8 mg kg–1 i.v., closed triangle)
or BG/glucose plus amiloride/DIDS and melphalan (closed circle). Means
± s.d. (n = 6)
Table 5 Time-schedule dependency of the combined treatment on the
tumour response
Time of treatment Regrowth time (days)
BG/glucose Amiloride/DIDS Melphalan
mean ± s.d. (n = 6–8)
0 h 0–0.5 h 3.5 h 8.4 ± 1.2
a0 h 2.5–3 h 3.5 h 8.1 ± 0.7
0 h 2.5–3 h 6 h 8.2 ± 1.3
aStandard protocol.Melphalan (8 mg kg–1; i.v.) was slightly potentiated by MIBG/
glucose, BG/glucose or amiloride/DIDS (Table 4). The combined
treatments further enhanced the tumour response (Table 4), and the
additional tumour growth delay of 2.4 days for BG/glucose plus
amiloride/DIDS is illustrated in Figure 5. Because of the delayed
pH-equilibrating effects of amiloride and DIDS observed in vitro,
simultaneous administration of BG/glucose and amiloride/DIDS or
delayed administration of melphalan were compared with the
standard protocol. All schedules appeared to be equally effective
(Table 5).
Pharmacokinetics and toxicity
The treatments MIBG/glucose plus amiloride/DIDS and BG/
glucose plus amiloride/DIDS combined with melphalan, mito-
mycin C or chlorambucil did not decrease body weight by more
than 10%, and no visible signs of illness were observed in any of
the combinations. To confirm that melphalan pharmacokinetics
were not changed in accordance with the absence of reduced
[51Cr]EDTA clearance, melphalan plasma levels were measured.
At 15, 60 and 120 min after drug administration, the melphalan
plasma levels were 3.7 ± 0.7, 1.0 ± 0.1 and 0.33 ± 0.05 mg ml–1
respectively. The tumour melphalan levels reflected plasma
concentrations. MIBG/glucose or BG/glucose treatment with or
without the addition of amiloride and DIDS did not significantly
affect melphalan levels in plasma and tumours.
DISCUSSION
Although tumour-selective pHe reduction is of demonstrated
importance in the response to the topoisomerase I inhibitor camp-
tothecin (Gabr et al, 1997), pH-mediated potentiation of several
clinically relevant drugs requires reduction of the intracellular pH
(Jähde et al, 1989; Atema et al, 1993). For this purpose, the
ionophore nigericin (Wood et al, 1995) and inhibitors of Na+/H+
and the Na+-dependent HCO3
–/Cl– exchanger (Yamagata and
Tannock, 1996) have demonstrated efficacy in vivo. Because the
level of the intracellular acidification is limited by extracellular pH
values (Wood et al, 1995), in the present study we tested the feasi-
bility of selectively reducing the extracellular pH of the tumour
before the administration of pH-equilibrating drugs.
The mitochondrial inhibitor MIBG, coadministered with
glucose, selectively reduces the intratumoral pH of RIF-1 tumours
down to pH 6.2, as demonstrated in a previous study (Kuin et al,
1994). In vitro acidification of murine leukaemic L1210 cells by
exposure to MIBG revealed comparable conditions as observed
in vivo: enhanced glycolytic flux, no change in the high energy
state and pH reduction of mainly the extracellular compartment.
Using MIBG for acidification, in vitro potentiation of cisplatin,
melphalan, mitomycin C and chlorambucil were comparable with
previous studies using hydrochloric acid or lactic acid (Jähde et al,
1989; Atema et al, 1993), and were independent of MIBG itself. In
addition, the mitomycin C derivative EO9 was strongly potenti-
ated at low pH conditions. The in vitro studies also confirmed the
predominant role of low pHi in these potentiations by stimulated
DNA alkylation of cisplatin and melphalan (Jähde et al, 1989;
Atema et al, 1993) and enhanced bioreductive activation of mito-
mycin C and EO9 (Gibson et al, 1992; Philips et al, 1992;
Begleiter and Leith, 1993). Furthermore, we confirmed that chlo-
rambucil is exclusively potentiated at low extracellular pH condi-
tions which, as a weak acid with a pKa value of 5.8, enhances its
uptake (Mikkelsen et al, 1985; Skarsgard et al, 1992). The oppo-
site was true for doxorubicin cytotoxicity because of a decreased
uptake at low pHe conditions (Alabaster et al, 1989).
Whereas potentiation of melphalan at low pH in the in vitro
studies is in agreement with literature, the observed synergism
between nigericin and melphalan at physiological pH (Figure 2)
was remarkable and basically not understood. Potentiation of
DNA alkylation by nigericin is unlikely because no interaction
with the structurally related chlorambucil was found. We, there-
fore, speculate that nigericin can stimulate melphalan uptake by
the Na+/amino acid symport. Because enhancement of melphalan
activity by nigericin was reported by Wood et al (1995) in only one
out of three tumour types, the observed synergism might be
restricted to certain cell types, which include L1210 cells.
Nigericin was abandoned early from in vivo studies because of
its possible interaction with melphalan, its effect on renal function
especially in combination with MIBG, and of its non-specific
action and unpredictable side-effects in human patients. The final
in vivo interventions of MIBG/glucose or BG/glucose with
amiloride and DIDS were not toxic when either applied alone or
combined with cytostatic drugs. Moreover, they did not reduce
renal clearance which could affect the tumour response by altered
pharmacokinetics.
In comparison to our previous study (Kuin et al, 1994), the
MIBG dose was reduced from 40 to 30 mg kg–1 or substituted for
the analogue BG. Comparable increases in tumour lactate levels
and deoxyglucose uptake indicated a similar decrease in pHe down
to 6.2, as was measured previously by pH electrodes. Because BG
lacks the ability of MIBG to increase plasma glucose levels by
sympathomimetic, stress-related gluconeogenesis (Kuin et al,
1994), more glucose (3 g kg–1) was needed for adequate support of
glycolysis. Although 31P MRS was not available to measure the
pHi, the pH modulation in the presence of amiloride and DIDS
revealed slight but significant anti-tumour responses, indicating a
reduction of the intracellular pH ≤ 6.5 for at least certain tumour
areas and sufficient time to induce cell kill (Rotin et al, 1987;
Newell and Tannock, 1989). This level of acidification is in
reasonable agreement with a calculated pHi of about 6.6, assuming
full equilibration of protons from the extracellular volume of 30%
of RIF-1 tumours (Evelhoch et al, 1984) at pHe 6.2. Variation in
the schedule of the combined treatment with melphalan (Table 5)
indicated that an effective low intratumoral pH persisted for at
least 6 h after the start of the treatment.
In contrast to the in vitro results, low tumour pHe did not
enhance chlorambucil-related tumour response. This was also in
conflict with reports on enhanced cell kill and tumour response
to chlorambucil simultaneously given with the vasoactive drugs
hydralazine (Skarsgard et al, 1992) or flavone acetic acid (Parkins
et al, 1994) to manipulate the pH. Perhaps the effect of drug trap-
ping by a strongly reduced tumour blood flow is more important
than a reduced pHe in these responses.
Reduced pHe combined with amiloride and DIDS enhanced
mitomycin C tumour response only in large sized tumours (>5 mm
diameter). Apparently, the manifestation of pH-mediated potentia-
tion of mitomycin C is dependent on conditions that specifically
exist in larger tumours, e.g. the extent of hypoxia and lower
perfusion rate (Vaupel et al, 1989). Moreover, Nishiyama et al
(1997) have demonstrated that tumour pH manipulation by
MIBG/glucose increased mitomycin C activity in some but not all
tumour types. Although the experimental bioreductive agent EO9
was most promising in vitro (Table 1), its low therapeutic index
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during clinical studies (Dirix et al, 1996).
So far, the combined treatment was most effective on melphalan
tumour response, which is in agreement with in vitro findings.
Amiloride/DIDS alone enhanced melphalan-induced tumour
growth delay by 1 day and also pHe reduction by MIBG/glucose
or BG/glucose alone slightly enhanced melphalan tumour
response. Accordingly, the tumour growth delay of the combined
treatment of 2.4 days might be due to a combined pH reduction.
The effects are less than the tumour growth delay of about 5 days
reported for the same tumour treated with melphalan plus nigericin
(Wood et al, 1995). The difference might be due to slower intracel-
lular acidification by amiloride and DIDS and a possible contribu-
tion of synergism between nigericin and melphalan. Moreover, it
is of note that in these studies melphalan alone caused minimal
tumour growth delay compared with 4 days in the present study.
In conclusion, we have developed a non-toxic intervention
using the mitochondrial inhibitor MIBG, or its analogue BG, plus
glucose in combination with amiloride and DIDS for a sustained
and selective reduction of tumour pHe to approximately 6.2 and
pHi to about 6.5–6.6. In contrast to nigericin, glucose and
amiloride are established clinical drugs and MIBG can safely be
given intravenously in doses up to 135 mg m–2 (B Taal,
Netherlands Cancer Institute, personal communication). An
important limitation in the present and a previous study (Gabr et
al, 1997), however, is that bolus injection of cytostatic drugs with
short half-lives are suboptimal to fully exploit the protracted pH
manipulation achieved by our protocol. The use of osmotic
minipumps in future studies might obviate this limitation.
Although intracellular tumour acidification per se is a potential
cytostatic intervention (Newell and Tannock, 1989; Yamagata and
Tannock, 1996), it contributed minimally to the potentiations
observed in the present study. Reduction of the intracellular pH in
vivo below critical values is thought to be self-limiting by inhibi-
tion of glycolytic key enzymes (Mansour, 1972) and a restricted
amount of protons in the extracellular volume. Accordingly,
reduction of the intracellular pH much below 6.5 would not seem
an attractive goal. Our results and those of Yamagata and Tannock
(1996) indicate that the anti-tumour effects will be maximal with
prolonged exposure to both pH-equilibrating drugs and selected
pHi-sensitive anti-cancer drugs.
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